Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma

NCT ID: NCT00003280

Last Updated: 2019-05-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 240 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1998-01-31
• Study Completion Date: 2002-03-31

Brief Summary

RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known which treatment regimen is more effective for lymphoma.

PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of rituximab in treating patients who have follicular or mantle cell lymphoma.

Detailed Description

OBJECTIVES:

• Assess the clinical efficacy of consolidation treatment with rituximab in terms of response rate in patients with follicular (closed to accrual 9/18/00) or mantle cell lymphoma.
• Compare the event free survival of patients after induction with or without consolidation.
• Compare the tolerability of these two treatment regimens by these patients.

OUTLINE: This is a randomized, open label, multicenter study. Patients are stratified according to participating center, histology (follicular (closed to accrual 9/18/00) vs mantle cell), status of disease (de novo vs relapsed vs resistant), response after induction (stable disease vs partial or complete response), and treatment status (treated vs untreated).

All patients receive induction therapy consisting of rituximab IV over 3-5 hours once a week during weeks 1-4. Patients are then randomized to one of two treatment arms.

• Arm I: Patients are observed.
• Arm II: Patients receive rituximab IV over 3-5 hours once a week during weeks 12, 20, 28, and 36.

Patients are followed weekly for the first month; every 8 weeks for the next 8 months; then at 12, 18, and 24 months; and then annually for the next 3 years.

PROJECTED ACCRUAL: A total of 240 patients (120 per arm) will be accrued for this study within 3-4 years.

Conditions

Lymphoma

Study Design

• Allocation Method: RANDOMIZED
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

rituximab

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically proven CD20 positive follicular (closed to accrual 9/18/00) or mantle cell lymphoma

• Untreated "de novo" disease OR
• Chemotherapy resistant disease OR
• Relapsing disease
• Bidimensionally measurable disease
• No symptomatic CNS disease

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• ECOG 0-2

Life expectancy:

• At least 3 months

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin no greater than 2 times upper limit of normal (ULN)
• No hepatitis B or C

Renal:

• Creatinine no greater than 2 times ULN

Cardiovascular:

• Ejection fraction at least 50%

Other:

• Not pregnant or nursing
• Fertile patients must use effective contraception
• No active opportunistic infections
• HIV negative
• No prior malignancy within 5 years except adequately treated carcinoma in situ of the cervix or localized nonmelanoma skin cancer

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No prior antibody based therapy

Chemotherapy:

• At least 4 weeks since prior chemotherapy (at least 6 weeks since nitrosoureas) and recovered
• No concurrent chemotherapy

Endocrine therapy:

• At least 4 weeks since prior corticosteroids, unless chronic dose no greater than 20 mg/day for nonlymphoma related condition
• No other concurrent corticosteroids

Radiotherapy:

• Not specified

Surgery:

• Not specified

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 120 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Swiss Cancer Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michele Ghielmini, MD

Role: STUDY_CHAIR

Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni

Locations

Kantonspital Aarau

Aarau, , Switzerland

Office of Walter Weber-Stadelman

Basel, , Switzerland

University Hospital

Basel, , Switzerland

Ospedale San Giovanni

Bellinzona, , Switzerland

Inselspital, Bern

Bern, , Switzerland

Hopital Cantonal Universitaire de Geneva

Geneva, , Switzerland

Istituto Oncologico della Svizzera Italiana

Lugano, , Switzerland

Burgerspital, Solothurn

Solothurn, , Switzerland

City Hospital Triemli

Zurich, , Switzerland

Klinik Hirslanden

Zurich, , Switzerland

Countries

Switzerland

References

Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Leger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 2005 Oct;16(10):1675-82. doi: 10.1093/annonc/mdi320. Epub 2005 Jul 19.

Reference Type: RESULT

PMID: 16030029 (View on PubMed)

Ghielmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer U, Fey MF, Betticher DC, Schefer H, Pichert G, Stahel R, Ketterer N, Bargetzi M, Cerny T; Swiss Group for Clinical Cancer Research. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005 Feb 1;23(4):705-11. doi: 10.1200/JCO.2005.04.164. Epub 2004 Dec 14.

Reference Type: RESULT

PMID: 15598978 (View on PubMed)

Lee CS, Ashton-Key M, Cogliatti S, Rondeau S, Schmitz SF, Ghielmini M, Cragg MS, Johnson P. Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98). Br J Haematol. 2015 Jan;168(1):145-8. doi: 10.1111/bjh.13071. Epub 2014 Aug 21. No abstract available.

Reference Type: RESULT

PMID: 25142001 (View on PubMed)

Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S, Okkinga E, Stupp R, Stahel R, Heizmann M, Vorobiof D, Lohri A, Dietrich PY, Zucca E, Ghielmini M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010 Oct 10;28(29):4480-4. doi: 10.1200/JCO.2010.28.4786. Epub 2010 Aug 9.

Reference Type: RESULT

PMID: 20697092 (View on PubMed)

Other Identifiers

SWS-SAKK-35/98

Identifier Type: -

Identifier Source: secondary_id

ICR-35/98

Identifier Type: -

Identifier Source: secondary_id

EU-98009

Identifier Type: -

Identifier Source: secondary_id

SAKK 35/98

Identifier Type: -

Identifier Source: org_study_id